Artios Pharma Limited

Advanced Solid Tumors

Artios Pharma Limited focuses on advanced or metastatic solid tumors, including advanced solid tumours and metastatic solid tumors, with clinical activity centered on patients whose disease has progressed beyond early-stage treatment options.

Solid tumor oncology
Metastatic disease
Advanced cancer

The sponsor’s clinical portfolio includes studies across multiple solid tumor settings, reflecting interest in difficult-to-treat oncology populations.

DNA Damage Response and Genome Instability

The research program is strongly aligned with DNA damage response biology, with trials in tumors characterized by ATM deficiency and related vulnerabilities in genomic instability.

ATM-negative cancers
Genomic repair pathways
Targeted oncology

These studies place emphasis on biologically defined cancer subsets where defects in DNA repair may shape therapeutic sensitivity.

Gastrointestinal and Pancreatic Cancers

Clinical research includes colorectal cancer and pancreatic ductal adenocarcinoma, along with acinar cell carcinoma, indicating a specific interest in aggressive gastrointestinal malignancies.

Colorectal cancer
Pancreatic cancer
Acinar cell carcinoma

These areas are represented in trials designed for patients with limited prior treatment options and advanced disease.

Gynecologic Oncology

Artios Pharma Limited also investigates high-grade serous ovarian carcinoma, primary peritoneal carcinoma, and fallopian tube carcinoma, with attention to platinum-resistant disease.

Ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer

This reflects a therapeutic focus on gynecologic cancers that remain challenging after standard platinum-based treatment.

Breast Cancer and BRCA-Associated Disease

The sponsor’s portfolio includes HER2-negative locally advanced or metastatic breast cancer with gBRCA mutation, linking its research to inherited susceptibility and homologous recombination-related tumor biology.